Home About us Pipeline News & Events Contact
Events

Archive

The Charcot-Marie-Tooth Association Enters Collaboration with Affectis to Advance Therapies for Charcot-Marie-Tooth 1A Disorder
Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
Affectis Pharmaceuticals and Merck Serono Announce an Agreement to Develop Oral Drugs for Neurodegenerative Diseases
Affectis Pharmaceuticals Appoints Manfred Rüdiger as Chief Executive Officer
Affectis Pharmaceuticals Raises €3.3M in Financing and Names Alex Martin Chief Executive Officer
Affectis Pharmaceuticals AG Receives Research Grant from the State of Bavaria Technology Program
Company Update – Affectis Pharmaceuticals strengthens its IP position
Affectis Pharmaceuticals and Mitsubishi Tanabe Pharma Enter Drug Discovery Collaboration
Affectis Pharmaceuticals AG Starts Phase II Clinical Trial with Cimicoxib for Depression
Affectis Pharmaceuticals AG Announces Extension of Research Collaboration with Mitsubishi Pharma
Dalton Pharma Services and Affectis Pharmaceuticals of Germany enter into a Contract Services Agreement
Affectis Pharmaceuticals AG In-licenses Clinical Stage Compound for the Treatment of Psychiatric Disorders
Affectis Pharmaceuticals AG attracts € 12 Million Venture Capital Investment, Strengthens Team